Taiho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Taiho Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5151
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Taiho Pharmaceutical Co Ltd (Taiho), a subsidiary of Otsuka Group develops and markets pharmaceutical products in the field of cancer, allergy, immunology, urology and others. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as vitamin tonic, herbal digestive medicine, topical analgesics, antifungal cream, herbal medicine powder, and others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries in Japan, China, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.

Taiho Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Taiho Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 13
Venture Financing 14
ORIC Pharma Raises USD50 Million in Series C Financing 14
Storm Therapeutics Raises Additional USD5.4 Million in Series A Financing 16
Arcus Biosciences Raises USD107 Million in Series C Financing 17
Harpoon Therapeutics Raises USD45 Million in series B Financing 19
Arcus Biosciences Raises USD70 Million in Series B Financing 21
Partnerships 22
Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma 22
X-Chem Enters into Agreement with Taiho Pharma 23
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 24
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 25
Response Genetics Extends Agreement With Taiho Pharma For Molecular Markers 26
Licensing Agreements 27
Taiho Pharma Enters into Licensing Agreement with Arcus Biosciences 27
TTY Biopharm Enters into Licensing Agreement with Taiho Pharma 28
Taiho Pharma Enters into Licensing Agreement with Servier 29
Taiho Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 30
Taiho Pharmaceutical Co Ltd – Key Competitors 31
Taiho Pharmaceutical Co Ltd – Key Employees 32
Taiho Pharmaceutical Co Ltd – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Strategy And Business Planning 34
Jun 02, 2017: Taiho Pharmaceutical to Construct Facility for Production of Highly Potent Pharmaceutical Ingredients 34
Mar 07, 2017: Taiho Pharmaceutical Announces Expansion into Canada 35
Product News 36
Oct 05, 2017: Taiho Pharmaceutical Releases Pitas Sore Throat Troche in Japan on October 5A Sticker-type Troche to be Placed on the Roof of the Mouth That is Helpful in Business Meetings 36
May 28, 2018: Taiho Pharmaceutical to Launch Tiovita Drink Aibitasu Zero Nationwide on May 28, 2018 “No fatigue the next day!” 37
Feb 07, 2017: Taiho Pharmaceutical Releases Pure Quick S Ointment, a New Mini Size Steroid Product 38
Clinical Trials 39
Apr 16, 2018: Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy 39
Other Significant Developments 40
Jul 03, 2018: Taiho Pharmaceutical Completes New Production Facility for Highly Potent Pharmaceutical Ingredients at Saitama Site 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Taiho Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Taiho Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Taiho Pharma Acquires Fermentation Research-Related Assets from Astellas Pharma 13
ORIC Pharma Raises USD50 Million in Series C Financing 14
Storm Therapeutics Raises Additional USD5.4 Million in Series A Financing 16
Arcus Biosciences Raises USD107 Million in Series C Financing 17
Harpoon Therapeutics Raises USD45 Million in series B Financing 19
Arcus Biosciences Raises USD70 Million in Series B Financing 21
Taiho Pharma Enters into Co-Marketing Agreement with Janssen Pharma 22
X-Chem Enters into Agreement with Taiho Pharma 23
Merck Enters into Co-Promotion Agreement with Taiho Pharma for Pembrolizumab 24
Taiho Pharma Enters into Co-Marketing Agreement with Meiji Seika Pharma 25
Response Genetics Extends Agreement With Taiho Pharma For Molecular Markers 26
Taiho Pharma Enters into Licensing Agreement with Arcus Biosciences 27
TTY Biopharm Enters into Licensing Agreement with Taiho Pharma 28
Taiho Pharma Enters into Licensing Agreement with Servier 29
Taiho Pharma Enters Into Licensing Agreement With Faes Farma For Bilastine 30
Taiho Pharmaceutical Co Ltd, Key Competitors 31
Taiho Pharmaceutical Co Ltd, Key Employees 32
Taiho Pharmaceutical Co Ltd, Subsidiaries 33

List of Figures
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Taiho Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Taiho Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Taiho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mazda Motor Corporation:戦略・SWOT・企業財務分析
    Mazda Motor Corporation - Strategy, SWOT and Corporate Finance Report Summary Mazda Motor Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Veristat LLC-製薬・医療分野:企業M&A・提携分析
    Summary Veristat LLC (Veristat), a subsidiary of Veristat Holding Inc is a clinical research organization that conducts clinical trials. The organization offers clinical monitoring, clinical project management, data management, CDISC implementation, biostatistics, medical writing, project management …
  • Ladbrokes plc:戦略・SWOT・企業財務分析
    Ladbrokes plc - Strategy, SWOT and Corporate Finance Report Summary Ladbrokes plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Biosceptre International Ltd-医療機器分野:企業M&A・提携分析
    Summary Biosceptre International Ltd (Biosceptre) is a biotechnology company that develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. The company develops imaging technologies to detect and monitor cancer. Biosceptre’s diagnostic products are …
  • Harmonic Inc (HLIT):企業の財務・戦略的SWOT分析
    Harmonic Inc (HLIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Joincare Pharmaceutical Group Industry Co Ltd (600380):製薬・医療:M&Aディール及び事業提携情報
    Summary Joincare Pharmaceutical Group Industry Co Ltd (Joincare Pharma) is a manufacturer and supplier of pharmaceutical products. The company offers healthcare products, bulk prescription products, active pharmaceutical ingredients, OTC products, detection reagents, and food additives. Its healthca …
  • Avara Pharmaceutical Services Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Avara Pharmaceutical Services Inc (Avara) is a contract development and manufacturing organization that provides primary formulation and manufacturing, secondary manufacturing and packaging of small molecules. It offers wide range of services such as manufacturing of active pharmaceutical in …
  • Oman Cables Industry (OCAI):企業の財務・戦略的SWOT分析
    Oman Cables Industry (OCAI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Covagen AG-製薬・医療分野:企業M&A・提携分析
    Summary Covagen AG (Covagen), a subsidiary of Cilag GmbH International is a biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb technology. The company’s pipeline products include COVA 322, a bispecific anti-tumor necrosis factor alpha …
  • Nestle Pakistan Limited:企業の戦略・SWOT・財務情報
    Nestle Pakistan Limited - Strategy, SWOT and Corporate Finance Report Summary Nestle Pakistan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • First Electric Cooperative Corporation:発電所・企業SWOT分析
    First Electric Cooperative Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informati …
  • Delcath Systems Inc (DCTH):製薬・医療:M&Aディール及び事業提携情報
    Summary Delcath Systems Inc (Delcath) specializes in developing percutaneous perfusion technologies to treat primary and metastatic liver cancers. Its patented drug delivery platform delivers ultra-high doses of anti-cancer drugs to the liver, while preventing them from entering the patient's bloods …
  • STATS ChipPAC Pte Ltd:企業の戦略的SWOT分析
    STATS ChipPAC Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Dermira Inc (DERM):製薬・医療:M&Aディール及び事業提携情報
    Summary Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an an …
  • Laborie Medical Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Laborie Medical Technologies Inc (Laborie), a subsidiary of Patricia Industries AB, develops and manufactures medical diagnostics and devices. The company offers uroflowmetry, urodynamics, pelvic floor rehabilitation and anorectal manometry products and related consumables. It also provides …
  • Stanley Black & Decker Inc:戦略・SWOT・企業財務分析
    Stanley Black & Decker Inc - Strategy, SWOT and Corporate Finance Report Summary Stanley Black & Decker Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Compania Espanola de Petroleos SAU-エネルギー分野:企業M&A・提携分析
    Summary Compania Espanola de Petroleos, S.A.U. (CEPSA) is an integrated energy company. It explores, produces, refines, transports and markets crude oil, petroleum products, and natural gas. It also produces and distributes electricity; manufactures, distributes, and sells basic petrochemicals, petr …
  • FIncantieri SpA:企業の戦略・SWOT・財務情報
    FIncantieri SpA - Strategy, SWOT and Corporate Finance Report Summary FIncantieri SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Kumagai Gumi Co Ltd (1861):企業の財務・戦略的SWOT分析
    Kumagai Gumi Co Ltd (1861) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • OpGen Inc (OPGN)-医療機器分野:企業M&A・提携分析
    Summary OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆